Stock Analysis on Net

Boston Scientific Corp. (NYSE:BSX)

This company has been moved to the archive! The financial data has not been updated since May 4, 2023.

Income Statement 
Quarterly Data

The income statement presents information on the financial results of a company business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.

Boston Scientific Corp., consolidated income statement (quarterly data)

US$ in millions

Microsoft Excel
3 months ended: Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Net sales 3,389 3,242 3,170 3,244 3,026 3,127 2,932 3,077 2,752 2,708 2,659 2,003 2,543 2,904 2,707 2,631 2,493 2,561 2,393 2,490 2,379
Cost of products sold (1,040) (1,010) (979) (1,011) (955) (972) (900) (945) (894) (999) (869) (791) (806) (850) (777) (758) (730) (728) (673) (739) (672)
Gross profit 2,349 2,232 2,191 2,233 2,071 2,155 2,032 2,132 1,858 1,709 1,790 1,212 1,737 2,054 1,930 1,873 1,763 1,833 1,720 1,751 1,707
Selling, general and administrative expenses (1,214) (1,163) (1,132) (1,164) (1,060) (1,153) (1,066) (1,121) (1,018) (1,028) (984) (798) (978) (1,092) (1,012) (968) (869) (954) (870) (885) (861)
Research and development expenses (337) (330) (339) (335) (319) (320) (310) (298) (276) (286) (315) (242) (300) (308) (306) (280) (280) (288) (289) (275) (261)
Royalty expense (11) (13) (11) (11) (12) (11) (14) (12) (12) (13) (12) (8) (12) (17) (15) (17) (16) (18) (17) (17) (18)
Amortization expense (203) (199) (202) (204) (198) (192) (184) (180) (185) (194) (197) (197) (201) (200) (178) (161) (160) (163) (148) (147) (141)
Goodwill impairment charges (73)
Intangible asset impairment charges (125) (7) (197) (128) (45) (9) (219) (34) (198) (1) (37) (67) (34) (1)
Contingent consideration net (expense) benefit (12) 33 (20) (36) (12) 19 26 85 6 (2) (6) 108 25 (8) (10) 28 9 13 4 (5)
Restructuring charges (20) (5) (4) (11) (4) (23) (9) (3) (5) (35) (3) (4) (10) (28) (3) (1) (6) (15) (3) (5) (13)
Litigation-related net (charges) credits (131) (42) (128) (298) (4) (19) (259) (223) (25) (15) 148 (85) (18)
Gain (loss) on disposal of businesses and assets (22) 30 40 2 6
Operating expenses (1,797) (1,830) (1,833) (1,810) (1,605) (1,975) (1,645) (1,870) (1,488) (1,659) (1,995) (1,283) (1,591) (1,844) (1,547) (1,489) (1,222) (1,514) (1,332) (1,359) (1,300)
Operating income (loss) 552 402 358 423 466 180 387 262 370 50 (205) (71) 146 210 383 384 541 319 388 392 407
Interest expense (65) (64) (63) (64) (279) (87) (86) (86) (82) (96) (86) (91) (88) (180) (95) (89) (109) (65) (58) (57) (61)
Other, net (43) 57 (50) (14) (31) 26 182 (27) 37 353 64 (19) (36) (36) (197) (150) 25 42 126 12 (23)
Other income (expense) (108) (7) (113) (78) (310) (61) 96 (113) (45) 257 (22) (110) (124) (216) (292) (239) (84) (23) 68 (45) (84)
Income (loss) before income taxes 444 395 245 345 156 119 483 149 325 307 (227) (181) 22 (6) 91 145 457 296 456 347 323
Income tax (expense) benefit (130) (255) (57) (85) (46) (24) (64) 37 16 (98) 72 34 (11) 4,002 35 9 (33) 90 (24) 208 (25)
Net income (loss) 314 140 188 260 110 95 419 186 341 209 (155) (147) 11 3,996 126 154 424 386 432 555 298
Preferred stock dividends (14) (15) (14) (14) (13) (14) (14) (14) (14) (13) (14) (6)
Net income (loss) available to common stockholders 300 125 174 246 97 81 405 172 327 196 (169) (153) 11 3,996 126 154 424 386 432 555 298

Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

Income statement item Description The company
Net sales Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. Boston Scientific Corp. net sales increased from Q3 2022 to Q4 2022 and from Q4 2022 to Q1 2023.
Operating income (loss) The net result for the period of deducting operating expenses from operating revenues. Boston Scientific Corp. operating income (loss) increased from Q3 2022 to Q4 2022 and from Q4 2022 to Q1 2023.
Income (loss) before income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Boston Scientific Corp. income (loss) before income taxes increased from Q3 2022 to Q4 2022 and from Q4 2022 to Q1 2023.
Net income (loss) The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Boston Scientific Corp. net income (loss) decreased from Q3 2022 to Q4 2022 but then increased from Q4 2022 to Q1 2023 exceeding Q3 2022 level.